A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ovarian cancer, outperforming the current gold standard.
A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in T-cell development and function.
MIT spinout Tissium recently secured FDA marketing authorization of a biopolymer platform for nerve repair.
EvoEndo announced today that it received expanded FDA clearance for its Model LE gastroscope, covering patients of all ages.
Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when blood flow is restored following a stroke.
Current methods for cancer diagnosis are based on identifying biomarkers—molecules that reveal a particular state or process in the body—produced by the tumor or associated proteins. Not surprisingly, these markers are more abundant once the tumor has already developed significantly. And the more advanced the tumor, the more difficult it is to find effective treatment options.
Scientists at UCSF have found that endometriosis—a painful chronic disease affecting 10% of women that often goes undiagnosed—often occurs alongside conditions like cancer, Crohn’s disease, and migraine.
Animals that hibernate are incredibly resilient. They can spend months without food or water, muscles refusing to atrophy, body temperature dropping to near freezing as their metabolism and brain activity slow to a crawl. When they emerge from hibernation, they recover from dangerous health changes similar to those seen in type 2 diabetes, Alzheimer’s disease, and stroke.
To diagnose either type 2 diabetes or pre-diabetes, clinicians typically rely on a lab value known as HbA1c. This test captures a person’s average blood glucose levels over the previous few months. But HbA1c cannot predict who is at highest risk of progressing from healthy to prediabetic, or from prediabetic to full-blown diabetes.
SetPoint Medical announced today that the FDA approved its SetPoint neuroimmune modulation system for treating rheumatoid arthritis (RA).